Molina, Ana M.

Publications

Sort by

Co-Author Network

selected publications

Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy. The Prostate. 2023 Academic Article GET IT
A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer. European urology. 2023 Letter GET IT
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. BMJ open. 2022 Academic Article GET IT
Times cited: 1
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
Times cited: 43
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Molecular oncology. 2022 Academic Article GET IT
Times cited: 4
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. British journal of cancer. 2022 Academic Article GET IT
Times cited: 6
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer. 2021 Academic Article GET IT
Times cited: 14
Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. The oncologist. 2021 Academic Article GET IT
Times cited: 6
Proteomic profile of the effects of low-dose bisphenol A on zebrafish ovaries. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2021 Academic Article GET IT
Times cited: 8
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clinical genitourinary cancer. 2021 Academic Article GET IT
Immunohistochemical expression of aromatase cyp19a1a and cyp19a1b in the ovary and brain of zebrafish (Danio rerio) exposed to different concentrations of bisphenol A. Aquatic toxicology (Amsterdam, Netherlands). 2021 Academic Article GET IT
Times cited: 4
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. European urology. 2021 Academic Article GET IT
Times cited: 23
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer. 2021 Academic Article GET IT
Times cited: 21
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 198
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer. The Prostate. 2021 Academic Article GET IT
Times cited: 7
Common germline-somatic variant interactions in advanced urothelial cancer. Nature communications. 2020 Academic Article GET IT
Times cited: 13
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO oncology practice. 2020 Review GET IT
Times cited: 23
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer. 2020 Academic Article GET IT
Times cited: 13
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷Lu-J591) for metastatic castration-resistant prostate cancer. Urologic oncology. 2020 Academic Article GET IT
Times cited: 20
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clinical genitourinary cancer. 2020 Academic Article GET IT
Times cited: 11
Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clinical genitourinary cancer. 2020 Academic Article GET IT
Times cited: 31
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (¹⁷⁷ Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. The oncologist. 2020 Academic Article GET IT
Times cited: 24
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. Investigational new drugs. 2020 Academic Article GET IT
Times cited: 8
Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma. Translational oncology. 2019 Academic Article GET IT
Times cited: 20
Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series. PloS one. 2019 Academic Article GET IT
Times cited: 8
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 36
Clinical features of neuroendocrine prostate cancer. European journal of cancer (Oxford, England : 1990). 2019 Academic Article GET IT
Times cited: 138
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature communications. 2019 Academic Article GET IT
Times cited: 102
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷ Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019 Academic Article GET IT
Times cited: 73
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. 2019 GET IT
Times cited: 4
Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 29
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. European journal of cancer (Oxford, England : 1990). 2018 Academic Article GET IT
Times cited: 28
A multidisciplinary approach for the management of earlier stage renal cell carcinoma. Urologic oncology. 2018 Review GET IT
Times cited: 3
Recommendations for the Management of Rare Kidney Cancers. European urology. 2017 Review GET IT
Times cited: 32
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 584
PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Editorial Article GET IT
Times cited: 6
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 57
Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature genetics. 2016 Academic Article GET IT
Times cited: 201
Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Editorial Article GET IT
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. The oncologist. 2016 Academic Article GET IT
Times cited: 74
Recent advances in the management of renal cell carcinoma. F1000Research. 2016 Review GET IT
Times cited: 4274
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma. The Journal of clinical endocrinology and metabolism. 2016 Academic Article GET IT
Times cited: 14
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer chemotherapy and pharmacology. 2015 Academic Article GET IT
Times cited: 62
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 689
Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. Critical reviews in oncology/hematology. 2015 Review GET IT
Times cited: 37
Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies. Frontiers in oncology. 2015 Review GET IT
Times cited: 49
Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis. Clinical genitourinary cancer. 2014 Academic Article GET IT
Times cited: 33
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT
Times cited: 66
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 1565
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. European journal of cancer (Oxford, England : 1990). 2013 Academic Article GET IT
Times cited: 87
Systemic treatment options for untreated patients with metastatic clear cell renal cancer. Seminars in oncology. 2013 Review GET IT
Times cited: 20
Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clinical genitourinary cancer. 2013 Academic Article GET IT
Times cited: 48
Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene. 2012 Academic Article GET IT
Times cited: 106
Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. American journal of clinical oncology. 2011 Academic Article GET IT
Times cited: 72
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011 Academic Article GET IT
Times cited: 99
mTOR inhibitors in advanced renal cell carcinoma. Hematology/oncology clinics of North America. 2011 Review GET IT
Times cited: 97
Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. The oncologist. 2011 Review GET IT
Times cited: 68
Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression. Cancer research. 2010 Academic Article GET IT
Times cited: 28
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Investigational new drugs. 2010 Academic Article GET IT
Times cited: 77
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. 2010 GET IT
Times cited: 10
Targeting renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Editorial Article GET IT
Times cited: 61
Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clinical genitourinary cancer. 2008 Review GET IT
Times cited: 33
Rare T-cell lymphomas. Cancer treatment and research. 2008 Review GET IT
Times cited: 1

more ...

less ...

Background

education and training

M.D., University of Miami School of Medicine 2003
B.S., Florida International University 1998

Contact

full name

Ana M. Molina

primary email

amm9052@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Ana M. Molina Assistant Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage